BioCryst Pharmaceuticals Inc
XMUN:BO1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
BioCryst Pharmaceuticals Inc
XMUN:BO1
|
US |
|
P
|
ProMIS Neurosciences Inc
F:23J
|
CA |
|
UniCredit SpA
MIL:UCG
|
IT |
|
M
|
MC Group PCL
SET:MC
|
TH |
|
Petmed Express Inc
NASDAQ:PETS
|
US |
|
Bed Bath & Beyond Inc
NYSE:BBBY
|
US |
|
China Mobile Ltd
F:CTM
|
CN |
Wall St Price Targets
BO1 Price Targets Summary
BioCryst Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for BO1 is 19.67 EUR with a low forecast of 11.615 EUR and a high forecast of 29.722 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is BO1's stock price target?
Price Target
19.67
EUR
According to Wall Street analysts, the average 1-year price target for BO1 is 19.67 EUR with a low forecast of 11.615 EUR and a high forecast of 29.722 EUR.
What is the Revenue forecast for BioCryst Pharmaceuticals Inc?
Projected CAGR
9%
Over the last 13 years, the compound annual growth rate for Revenue has been 31%. The projected CAGR for the next 8 years is 9%.
What is the Gross Profit forecast for BioCryst Pharmaceuticals Inc?
Projected CAGR
9%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 31%. The projected CAGR for the next 8 years is 9%.
What is the Operating Income forecast for BioCryst Pharmaceuticals Inc?
Projected CAGR
10%
The compound annual growth rate for Operating Income over the next 8 years is 10%.
What is the Pre-Tax Income forecast for BioCryst Pharmaceuticals Inc?
Projected CAGR
-7%
The compound annual growth rate for Pre-Tax Income over the next 3 years is -7%.
What is the Net Income forecast for BioCryst Pharmaceuticals Inc?
Projected CAGR
20%
The compound annual growth rate for Net Income over the next 8 years is 20%.
